What is First Tracks Biotherapeutics?
operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.98B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.